HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vallabhajosula, S. Articles by Bander, N. H. Search for Related Content PubMed PubMed Citation Articles by Vallabhajosula, S. Articles by Bander, N. H.

Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using ⁹⁰Y- and ¹⁷⁷Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen

¹ Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital–Weill Medical College of Cornell University, New York, New York
² Division of Hematology and Medical Oncology, New York Presbyterian Hospital–Weill Medical College of Cornell University, New York, New York
³ Laboratory of Urological Oncology, Department of Urology, New York Presbyterian Hospital–Weill Medical College of Cornell University, New York, New York

In radioimmunotherapy, myelotoxicity due to bone marrow radiation-absorbed dose is the predominant factor and frequently is the dose-limiting factor that determines the maximum tolerated dose (MTD). With ⁹⁰Y- and ¹³¹I-labeled monoclonal antibodies, it has been reported that myelotoxicity cannot be predicted on the basis of the amount of radioactive dose administered or the bone marrow radiation-absorbed dose (BMrad), estimated using blood radioactivity concentration. As part of a phase I dose-escalation study in patients with prostate cancer with ⁹⁰Y-DOTA-J591 (DOTA = 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) (⁹⁰Y-J591) and ¹⁷⁷Lu-DOTA-J591 (¹⁷⁷Lu-J591), we evaluated the potential value of several factors in predicting myelotoxicity. Methods: Seven groups of patients (n = 28) received 370–2,775 MBq/m² (10–75 mCi/m²) of ¹⁷⁷Lu-J591 and 5 groups of patients (n = 27) received 185–740 MBq (5–20 mCi/m²) of ⁹⁰Y-J591. Pharmacokinetics and imaging studies were performed for 1–2 wk after ¹⁷⁷Lu treatment, whereas patients receiving ⁹⁰Y had these studies performed with ¹¹¹In-DOTA-J591 (¹¹¹In-J591) as a surrogate. The BMrad was estimated based on blood radioactivity concentration. Myelotoxicity consisting of thrombocytopenia or neutropenia was graded 1–4 based on criteria of the National Cancer Institute. Results: Blood pharmacokinetics are similar for both tracers. The radiation dose (mGy/MBq) to the bone marrow was 3 times higher with ⁹⁰Y (0.91 ± 0.43) compared with that with ¹⁷⁷Lu (0.32 ± 0.10). The MTD was 647.5 MBq/m² with ⁹⁰Y-J591 and 2,590 MBq/m² with ¹⁷⁷Lu-J591. The percentage of patients with myelotoxicity (grade 3–4) increased with increasing doses of ⁹⁰Y (r = 0.91) or ¹⁷⁷Lu (r = 0.92). There was a better correlation between the radioactive dose administered and the BMrad with ¹⁷⁷Lu (r = 0.91) compared with that with ⁹⁰Y (r = 0.75). In addition, with ¹⁷⁷Lu, the fractional decrease in platelets (FDP) correlates well with both the radioactive dose administered (r = 0.88) and the BMrad (r = 0.86). In contrast, with ⁹⁰Y, there was poor correlation between the FDP and the radioactive dose administered (r = 0.20) or the BMrad (r = 0.26). Similar results were also observed with white blood cell toxicity. Conclusion: In patients with prostate cancer, myelotoxicity after treatment with ¹⁷⁷Lu-J591 can be predicted on the basis of the amount of radioactive dose administered or the BMrad. The lack of correlation between myelotoxicity and ⁹⁰Y-J591 BMrad may be due to several factors. ⁹⁰Y-J591 may be less stable in vivo and, as a result, higher amounts of free ⁹⁰Y may be localized in the bone. In addition, the cross-fire effect of high-energy ß^–-particles within the bone and the marrow may deliver radiation dose nonuniformly within the marrow.

Key Words: radioimmunotherapy • myelotoxicity • ¹⁷⁷Lu-labeled J591 monoclonal antibody

Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 8a-9a. [Full Text]  

This article has been cited by other articles:

				S. Vallabhajosula, S. J. Goldsmith, L. Kostakoglu, M. I. Milowsky, D. M. Nanus, and N. H. Bander Radioimmunotherapy of Prostate Cancer Using 90Y- and 177Lu-Labeled J591 Monoclonal Antibodies: Effect of Multiple Treatments on Myelotoxicity Clin. Cancer Res., October 1, 2005; 11(19): 7195s - 7200s. [Abstract] [Full Text] [PDF]